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It has been shown in the past 30 years that Hodgkin lymphoma 
(HL) comprises two different B-cell disease entities, namely classic 
HL (CHL) and nodular lymphocyte-predominant HL. Although gene 
expression profiling shows that these two types of HL have similarities, 
they differ considerably in their morphology, immunophenotype and 
clinical course. CHL comprises ~95% of all lymphomas and is further 
subclassified into four different histological variants, namely nodular 
sclerosis HL (CHL-NS), mixed-cellularity HL (CHL-MC), lymphocyte-
rich HL (CHL-LR) and lymphocyte-deplete HL (CHL-LD).[1]
HL is the most common non-AIDS-defining cancer in HIV-
positive patients, who are at 8 - 10 times higher risk than HIV-
negative individuals. In 2016, it was estimated that 12.7% (7.03 
million) of the population aged 15 - 49 years in South Africa (SA) was 
HIV-positive, compared with 10.8% (5.1 million) in 2005.
The global incidence of HL increased by 12.9% between 2005 
and 2015.[2] This rise in incidence largely seems to be linked to HIV 
infection. Several studies conducted at SA tertiary hospitals have 
described the prevalence of HL as 7 - 17% of all lymphomas,[3-6] 
8 - 27% of head and neck lymphomas,[7,8] 9% of lymph node biopsies 
and 4% of HIV-related malignancies[9] presenting at the respective 
hospitals. HIV seropositivity in these cases ranged between 8% and 
67%.[3-6,8] The most common subtypes documented were CHL-MC 
and CHL-NS.[6,8]
There are few epidemiological studies of HL in other African 
countries, with previous studies showing prevalences of HL between 
0.5% and 2% of all malignancies,[10,11] 7 - 12.5% of all lymphomas[12] and 
7 - 11% of all lymph node biopsies[13] investigated. HIV seropositivity 
ranged between 0% and 16%,[10-14] with some studies not testing for 
HIV owing to lack of availability of the means to do so.[10,11,13] A 
multi-African study[14] (n=52 cases) and a Nigerian study[11] (n=80) 
described CHL-MC and CHL-NS as the most common subtypes, 
whereas studies in Nigeria[13] (n=56) and Malawi[12] (n=31) recorded 
a predominance of CHL-MC and CHL-LD.
It is reported that HIV-positive patients on antiretroviral therapy 
(ART) with a higher CD4+ count are at higher risk of developing 
CHL than patients with a lower CD4+ count. The risk of developing 
HL is highest when the CD4+ count is between 150 and 199 cells/µL. 
There are several theories regarding the role of ART. One is that ART 
increases the CD4+ count, which the Hodgkin Reed-Sternberg (HRS) 
cells are dependent on for their growth. A second theory is that the 
HRS cell is a crippled B-cell and therefore not directly affected by 
HIV. As these HRS cells are B-cells they attract CD4+ T-cells, and the 
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increase in CD4+ T-cells is therefore a consequence of the tumour 
cell. A third theory is that there are competing risks, in that patients 
with lower CD4+ counts are more likely to suffer from AIDs-defining 
illnesses.[1]
As CHL has previously been shown to be dependent on CD4+ 
counts in HIV-positive patients, it is vital that we establish the 
baseline incidence and the impact of ART rollout on the incidence 
of HL in our institution over the past decade. Initiation of ART in 
the public sector in SA was implemented in patients with a CD4+ 
count of <200 cells/µL in 2004. This changed to <350 cells/µL in 2013 
and then to <500 cells/µL in 2015. The 2017 Adult Antiretroviral 
Therapy Guideline recommendation is to treat HIV-positive patients 
independent of the baseline CD4+ count.
Objectives
The prevalence of HL at our centre, Tygerberg Academic Hospital 
(TAH) in the Western Cape Province of SA, was 17% of all lymphomas 
diagnosed between 2002 and 2009 (n=187 cases); 8% of HL patients 
were HIV-positive.[5] The objective of this study was to expand on this 
previous prevalence study of all lymphomas conducted at our centre[5] 
by describing in more detail the incidence of HL between 2005 and 
2016 by year, gender, HIV status, histological subclassification and 
bone marrow involvement, and to compare these findings with other 
SA and African studies describing HL.
Methods
A retrospective study of HL cases diagnosed in the Division of 
Anatomical Pathology and the Division of Haematopathology, 
Department of Pathology, National Health Laboratory Service 
(NHLS), TAH, was conducted. TAH is a 1 380-bed tertiary referral 
academic hospital affiliated to Stellenbosch University and services 
approximately half of the population of the Western Cape (total 
population ~6.3 million). Cases were collected from 1 January 2005 to 
31 December 2016 and form part of the ongoing Tygerberg Lymphoma 
Study Group database (Human Research Ethics Committee ref. no. 
N07/03/068) established in 2007 in the Division of Haematopathology 
with the aim of documenting all lymphoma cases presenting at TAH. [5] 
Patient demographic, HIV test, CD4+ count, lymph node and bone 
marrow biopsy data for this database were extracted from the DisaLab 
version 04.16.04.373 (Laboratory System Technology (Pty) Ltd, South 
Africa) (up to August 2015) and TrakCare v6.10 (InterSystems, 
Australia) laboratory information systems. Ethical approval of the study 
was granted by the Health Research Ethics Committee, Stellenbosch 
University (ref. no. S15/09/206).
Case definition
A positive diagnosis of HL was confirmed either by lymph node 
biopsy assessment reported by the Division of Anatomical Pathology 
or by bone marrow biopsy assessment reported by the Division of 
Haematopathology. A staging bone marrow biopsy was routinely 
performed on all lymph node biopsy-positive lymphoma patients 
at our centre. The lymph node and bone marrow biopsy diagnoses 
were based on morphological and immunohistochemical findings in 
accordance with the 2008 World Health Organization classification of 
tumours of haematopoietic and lymphoid tissues. The bone marrow 
biopsy procedure and reporting format followed the International 
Council for Standardisation in Haematology guidelines.
Inclusion and exclusion criteria
All incident cases of HL of all ages presenting between 1 January 
2005 and 31 December 2016 were included in the study. Follow-up, 
relapsed and referral cases of HL were excluded.
Patient variables
Demographic characteristics (age and gender), date of diagnosis, HIV 
status (using enzyme-linked immunosorbent assay HIV serology 
testing), CD4+ count (using flow cytometry pan-leucocyte gating 
techniques), HIV viral load (measured by quantitative RNA-based 
testing using the Amplicor HIV-1 Monitor Test (Roche Diagnostics, 
USA)), HL subclassification and presence of bone marrow 
involvement of HL (stage 4 disease) were collected. Age ranges for 
analysis were selected as per the 2012 South African National HIV 
Prevalence, Incidence and Behavioural Survey for comparability.
Data analysis
Statistical analysis of all data was performed using Excel 2016 
(Microsoft, USA) and SPSS v20 (SPSS, USA). Results were 
summarised and presented by year, gender and HIV status using 
descriptive statistical methods. As HL is an HIV-related tumour, all 
variables were analysed by HIV status.
Results
There were 303 incident cases of HL (56.4% male and 43.6% female) 
diagnosed between 2005 and 2016 (Table 1).
Year
There was an increasing trend in incidence of cases in both HIV-positive 
and HIV-negative patients from 2005 to 2011, with a spike in cases in 
2008. There was a subsequent overall decline after 2011 (Fig. 1).
Age
The mean (standard deviation (SD)) age at diagnosis of HL, 
independent of HIV status, was 33.4 (15.9) years. There was no 
significant difference in the mean age at diagnosis of HL between 
the HIV-positive and HIV-negative groups (Table 1). The highest 
number of cases was found in the 25 - 49-year age range category 
(n=155, 51.1%) (Table 1 and Fig. 2).
Gender
There was no statistically significant difference in gender between the 
HIV-positive and HIV-negative groups (p=0.14).
HIV status and CD4+ count
Only 81.2% (n=246) of our sample had confirmation of HIV testing. 
There were 77 HIV-positive patients (25.4%), of whom 64 (21.1%) 
had CD4+ counts reported. There were 169 HIV-negative patients 
(55.8%) and 57 patients with unknown HIV status (18.8%). In 
the HIV-positive group, 43 patients (55.8%) had a CD4+ count of 
<350 cells/µL at the time of diagnosis, whereas 53 patients (71.4%) 
had a count of <500 cells/µL. Only 30 patients (39.0%) had a count 
of <200 cells/µl (Table 2). The 2015 SA HIV management guidelines 
recommended changing initiation of treatment in all HIV-positive 
patients from CD4+ <350 cells/µL to <500 cells/µL. The mean (SD) 
CD4+ count at the time of diagnosis for those tested was 225 (173) 
cells/µL).
Histological subtype
There were 280 cases of HL (92.4%) diagnosed by lymph node biopsy. 
The most frequent subtypes identified were CHL-NS (151 cases, 
49.8% of all subtypes identified) and CHL-MC (70 cases, 23.1%) 
(Fig. 3). Of those patients tested for HIV, more were HIV-negative in 
these two subtypes (72.2% v. 67.6%) (Table 1 and Fig. 3).
Bone marrow involvement (stage 4 disease)
Bone marrow biopsy following lymph node diagnosis of HL con-
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firmed involvement of the bone marrow in 72 patients (23.7%), 
while 168 patients (55.4%) did not have bone marrow involvement 
(Table 1 and Fig. 4). Of patients with bone marrow involvement, 
roughly equal numbers were HIV-positive (48.6%) and HIV-negative 
(45.8%). There were 29 HIV-positive HL patients who did not have 
bone marrow involvement.
There were 14 cases of HL that were initially diagnosed from 
incidental bone marrow biopsies for investigation of pancytopenia 
or bicytopenia. Subtyping of HL is currently not performed on bone 
marrow biopsy specimens.
Table 1. Selected characteristics of all HL cases by HIV status, 2005 - 2016
Characteristics 
HIV status (N=303)
Total p-value
HIV-positive 
(n=77, 25.4%)
HIV-negative 
(n=169, 55.8%)
Unknown 
(n=57, 18.8%)
Age (yr), mean (SD)  34.4 (10.5) 32.2 (16.7) 35.6 (19.1)   0.24
Age (yr), n (%)        
0 - 14 2 (2.6) 21 (12.4) 8 (14.0) 31 (10.2)
15 - 24 10 (13.0) 41 (24.3) 8 (14.0) 59 (19.5)
25 - 49 59 (76.6) 71 (42.0) 25 (43.9) 155 (51.1)
50 - 59 5 (6.5) 25 (14.8) 8 (14.0) 38 (12.5)
≥60 1 (1.3) 11 (6.5) 8 (14.8) 20 (6.6)
Gender, n (%) 0.14
Male 38 (49.4) 101 (59.8) 32 (56.7) 171 (56.4)
Female 39 (50.6) 68 (40.2) 25 (43.9) 132 (43.6)
Histological subtype (based on lymph node diagnosis), n (%)
CHL (no subclassification) 7 (9.1) 20 (11.8) 4 (7.0) 31 (10.2)
CHL-NS 32 (41.6) 88 (52.1) 31 (54.4) 151 (49.8)
CHL-MC 20 (26.0) 34 (20.1) 15 (26.3) 69 (22.7) 
CHL-LR 3 (3.9) 6 (3.6) 0 9 (3.0)
CHL-LD 3 (3.9) 3 (1.8) 3 (5.3) 9 (3.0)
NLPHL 0 8 (4.7) 2 (3.5) 10 (3.3)
Inconclusive 12 (15.6) 10 (5.9) 2 (3.5) 24 (7.9)
Bone marrow involvement, n (%)
Yes 35 (45.5) 33 (19.5) 4 (7.0) 72 (23.7)
Bone marrow diagnosis 8 (10.3) 5 (2.9) 1 (1.8) 14 (4.6)
No 29 (37.7) 121 (71.6) 18 (31.6) 168 (55.4)
Not done 12 (15.6) 13 (7.7) 35 (61.4) 60 (19.8)
Inadequate bone marrow 1 (1.3) 2 (1.2) 0 3 (1.0)
HL = Hodgkin lymphoma; CHL = classic HL; CHL-NS = nodular sclerosis CHL; CHL-MC = mixed-cellularity CHL; CHL-LR = lymphocyte-rich CHL; CHL-LD = lymphocyte-depleted CHL; 
NLPHL = nodular lymphocyte-predominant CHL.
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Fig. 1. Number of incident Hodgkin lymphoma cases by year and HIV status, 
2005 - 2016.
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Fig. 2. Age distribution of Hodgkin lymphoma cases by HIV status, 2005 - 2016.
Table 2. Number and percentage of patients in CD4+ categories, 2005 - 2016
CD4+ cell count (cells/µL)
Total<50 51 - 149 150 - 199 >200 Unknown
Patients, n (%) 10 (13.0) 12 (15.6) 8 (10.4) 34 (44.2) 13 (16.8)  77
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Discussion
Our study identified 303 new cases of HL at Tygerberg Hospital 
between 2005 and 2016 by lymph node biopsy diagnosis (93.4%) or 
bone marrow biopsy diagnosis (4.6%). HL was not identified in any 
other extranodal sites.
Increasing trend in HL incidence from 2005 to 2011
The global incidence of HL increased by 12.9% between 2005 and 
2015.[2] Similarly, a previous study at our institution between 2002 
and 2009 showed an increased incidence of all lymphomas, including 
more rare types such as Burkitt lymphoma and plasmablastic 
lymphoma, in both HIV-positive and HIV-negative patients.[5]
The increasing trend in the incidence of HL in our population 
between 2005 and 2011 is influenced by multifactorial causes. 
Firstly, ART rollout for HIV-positive patients in the public health 
sector commenced in 2004. Secondly, urbanisation with migration 
of people to the Western Cape from other areas of SA and other 
African countries may have contributed to the increase. International 
guidelines for the diagnosis and treatment of HL suggest HIV testing 
as part of risk stratification. Unfortunately, testing for HIV in SA 
carried a social stigma during the early rise of HIV disease. This 
resulted in fewer suspected lymphoma patients being tested and 
therefore could have influenced our data. This is possibly evidenced 
by the 18.8% of patients of unknown HIV status in our data, with 
the majority of these cases before 2012 (66.7%). Although our study 
showed that overall more incident cases of HL were HIV-negative, 
the proportion of patients who were HIV-positive was noted to be 
on the rise.
Combined ART has been shown to improve survival in HL patients. 
The total number of patients receiving ART in SA increased from 
47 500 in mid-2004 to 1.79 million in mid-2011, with ~85% of 
these patients receiving ART through the public health sector.[15] 
There were 5 000 patients on ART in the Western Cape in 2004, the 
figure increasing to 107 000 by 2011 in the public, private and non-
governmental organisation sectors combined. The percentage of new 
patients on ART ranged between 34% and 64% each year. From 2004 
to 2011, there were twice as many women than men on ART.[15] These 
increases in ART coverage would be likely to affect the epidemiology 
of HIV-related lymphomas presenting at our institution.
Early epidemiological studies have suggested a possible association 
between ART and the incidence of HL. The risk of HL increased by 
68% in HIV-positive patients since ART was introduced in the USA 
(1996 - 2002) compared with the previous period of no ART (1990 
- 1995).[16]
HIV status and CD4+ count
A higher proportion of cases in our study population were HIV-
negative (55.8%) than HIV-positive (25.4%). Of the HIV-positive 
patients, 54.6% had a CD4+ count >150 cells/µL, which is consistent 
with a US population study of HL from 1980 to 2002 that showed 
significantly more patients with CD4+ counts of 150 - 199 cells/µL 
compared with <50 cells/µL.[17] None of the studies on HL in African 
populations reviewed had documented CD4+ counts.
A study of several US states linking HIV/AIDS and cancer registry 
data in patients to identify HL cases (1980 - 2002, n=173 cases) 
concluded that patients with moderate levels of immunodeficiency 
(CD4+ count 150 - 199 cells/µL) were at higher risk of developing 
HL than those with more severe levels of immunodeficiency (CD4+ 
count <50 cells/µL). Furthermore, in another study the mean CD4+ 
count at diagnosis of HL was 210 cells/µL, which was found to be 
relatively high compared with other HIV-associated non-HL.[18] Our 
study found that ~55% of HIV-positive HL patients had a CD4+ 
count >150 cells/µL, in keeping with the US study. This finding 
further supports the hypothesis that the tumour microenvironment 
(non-neoplastic reactive cells) releases feedback cytokines and 
chemokines that stimulate the proliferation or inhibition of apoptosis 
of HRS cells.[18]
However, a subsequent Swiss cohort of HIV-positive patients 
followed up for 20 years (n=14 606) concluded there was no evidence 
of increased HL risk with ART and improved immunity. A study in 
Uganda (1999 - 2008) evaluated the effect of ART on HIV-related 
cancer incidence and further concluded that there was no association 
between increased ART coverage and incidence of HL (n=153 cases).[19]
Age and gender
HIV seroprevalence in this study population was highest in the 25 - 
49-year age group (76.6%), which is also the age group most affected 
by HIV in SA. There was no difference between male and female 
patients in our study, which is in keeping with a previous study in 
several sub-Saharan African countries[14] and in Western populations.
Decreasing trend from 2012 to 2016
Although the trend from 2012 to 2016 differs from that for 2005 to 
2011, absolute numbers of HL have increased since 2005. Further 
investigation is necessary to identify the underlying causes for these 
differences during this period.
Histological subtype
The predominant subtypes (CHL-MC and CHL-NS) in HIV-
Unknown
HIV-negative
HIV-positive
Unknown
HIV-negative
HIV-positive
CHL
CHL-NS
CHL-MC
CHL-LR
CHL-LD
NLPHL
Inconclusive
 Cases, n
Bone marrow involved
Bone marrow not involved
Unknown
Inconclusive
0        20        40        60        80       100      120     140    160      180
Su
bt
yp
e
0       20       40       60       80       100       120       140       160
 Cases, n
Fig. 3. Hodgkin lymphoma subtype by HIV status (based on lymph node 
diagnosis), 2005 - 2016. (CHL = classic Hodgkin lymphoma; CHL-NS  = 
nodular sclerosis CHL; CHL-MC = mixed-cellularity CHL; CHL-LR = 
lymphocyte-rich CHL; CHL-LD = lymphocyte-depleted CHL; NLPHL = 
nodular lymphocyte-predominant CHL.)
Unknown
HIV-negative
HIV-positive
Unknown
HIV-negative
HIV-positive
CHL
CHL-NS
CHL-MC
CHL-LR
CHL-LD
NLPHL
Inconclusive
 Cases, n
Bone marrow involved
Bone marrow not involved
Unknown
Inconclusive
0        20        40        60        80       100      120     140    160      180
Su
bt
yp
e
0       20       40       60       80       100       120       140       160
 Cases, n
Fig. 4. Bone marrow involvement by HIV status, 2005 - 2016.
567       July 2018, Vol. 108, No. 7
RESEARCH
positive patients are in keeping with previous SA studies[6-8] and 
with two African studies.[11,14] Two other African studies showed a 
predominance of CHL-MC and CHL-LD.[12,13] In contrast, the most 
common HL subtypes in Western populations are CHL-MC and 
CHL-LD.
Bone marrow involvement (stage 4 disease)
Our HL population included 72 cases (23.7%) with bone marrow 
involvement, compared with 6 cases (50%) in a recent Malawian 
study.[12] Of these 72 patients, 14 (19.4%) were initially diagnosed 
by bone marrow biopsy. This finding supports clinical observations 
that HIV-positive patients with lymphoma may present atypically. In 
our setting, the diagnosis of lymphoma may be delayed owing to the 
increase of concomitant TB and HIV, as the clinical presentations 
overlap. HIV patients may therefore present with extensive disease. 
This is an important finding, and we recommend that clinicians have 
a high index of suspicion when HIV-positive patients present with 
suggestive clinical features, namely B-cell symptoms.
Study strengths and limitations
A strength of our study was the long period of observation and 
the comprehensive laboratory information management systems 
at TAH. Limitations include the retrospective study design and 
incomplete data on the HIV status of 18.8% of the cohort. Further, 
we did not have data on ART use in this cohort. We also did not 
have data on patients diagnosed at other centres/departments or 
in the private health sector and then subsequently referred to TBH 
for treatment.
Conclusions
Our study showed that the absolute numbers of HL at our centre 
increased over the 10 years after roll-out of ART to the public sector. 
The change in recent policy of ART availability to all HIV-positive 
patients independent of CD4+ count suggests that patients will 
survive longer and are therefore at increased risk of developing 
HL. Based on the study findings, we anticipate that numbers of HL 
cases will increase or remain high in the coming years, and we need 
to increase awareness and to prepare for this. Finally, our findings 
highlight the value of a regional and national cancer registry linked 
to an HIV test result database for the monitoring of HIV-related 
malignancies such as HL.
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